Lancet:51例患者随机研究!“治愈”的扩心病患者能否停药?

2019-01-16 文韬 中国循环杂志

阜外医院张健等曾发表一项研究称,对于高血压心衰患者,如果给予标准的抗心力衰竭治疗,可以是三成患者“治愈”。即:左室射血分数明显提高,左室明显缩小。


阜外医院张健等曾发表一项研究称,对于高血压心衰患者,如果给予标准的抗心力衰竭治疗,可以是三成患者“治愈”。即:左室射血分数明显提高,左室明显缩小。

但问题是,这些看起来已和正常人类似的患者,能否停药?

最近,Lancet一项随机研究仅仅入选了51个扩张性心肌病患者,尝试回答了这个问题。

这51个患者在治疗后射血分数已提高到50%以上,NT-pro-BNP已小于250ng/L。随机分为两组。一组停药,另一组继续服药。

如果LVEF降低超过10%并且低于50%,左室大小升高超过10%且高于正常值,NT-pro-BNP升高超过400ng/L以上,或有心力衰竭的临床证据,定义为心衰复发。

结果发现,25名被随机分配到中断治疗组的患者中,有11名达到了复发标准。而继续服药组仅有1人复发。

研究还发现,撤药组的心率明显上升,尤其在复发患者中最为明显,表明β受体阻滞剂的停药可能是一个重要因素。

作者认为,经过治疗,扩张型心肌病已明显缓解的患者如果停药,心衰会复发,所以治疗应该长期维持下去。

研究中,患者使用的药物包括:袢利尿剂、β受体阻滞剂、血管紧张素转换酶(ACE)抑制剂、血管紧张素受体阻滞剂(ARB)或盐皮质激素受体拮抗剂(MRA)或这几种药物的组合。

作者称,这是第一项心力衰竭患者的“撤药”试验,证实有40%的患者在停药后复发。

51例患者中,35例为特发性扩张型心肌病,7例为家族性扩张型心肌病,9例为继发性扩张型心肌病,包括酒精性心肌病、围产期心肌病、使用蒽环类药物、甲状腺功能亢进和既往心肌炎。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1935135, encodeId=4fc5193513563, content=<a href='/topic/show?id=dc5a54e869c' target=_blank style='color:#2F92EE;'>#扩心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54786, encryptionId=dc5a54e869c, topicName=扩心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 23 14:06:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829928, encodeId=c57f182992840, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jul 13 12:06:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941975, encodeId=078719419e5c4, content=<a href='/topic/show?id=338b98462fa' target=_blank style='color:#2F92EE;'>#随机研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98462, encryptionId=338b98462fa, topicName=随机研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Tue Feb 12 08:06:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460831, encodeId=0c0f14608318b, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Fri Jan 18 13:06:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358474, encodeId=b30d3584e4e2, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jan 17 21:56:44 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358465, encodeId=3ad13584659d, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef781002, createdName=topnew, createdTime=Thu Jan 17 19:12:21 CST 2019, time=2019-01-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1935135, encodeId=4fc5193513563, content=<a href='/topic/show?id=dc5a54e869c' target=_blank style='color:#2F92EE;'>#扩心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54786, encryptionId=dc5a54e869c, topicName=扩心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 23 14:06:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829928, encodeId=c57f182992840, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jul 13 12:06:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941975, encodeId=078719419e5c4, content=<a href='/topic/show?id=338b98462fa' target=_blank style='color:#2F92EE;'>#随机研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98462, encryptionId=338b98462fa, topicName=随机研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Tue Feb 12 08:06:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460831, encodeId=0c0f14608318b, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Fri Jan 18 13:06:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358474, encodeId=b30d3584e4e2, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jan 17 21:56:44 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358465, encodeId=3ad13584659d, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef781002, createdName=topnew, createdTime=Thu Jan 17 19:12:21 CST 2019, time=2019-01-17, status=1, ipAttribution=)]
    2019-07-13 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1935135, encodeId=4fc5193513563, content=<a href='/topic/show?id=dc5a54e869c' target=_blank style='color:#2F92EE;'>#扩心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54786, encryptionId=dc5a54e869c, topicName=扩心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 23 14:06:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829928, encodeId=c57f182992840, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jul 13 12:06:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941975, encodeId=078719419e5c4, content=<a href='/topic/show?id=338b98462fa' target=_blank style='color:#2F92EE;'>#随机研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98462, encryptionId=338b98462fa, topicName=随机研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Tue Feb 12 08:06:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460831, encodeId=0c0f14608318b, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Fri Jan 18 13:06:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358474, encodeId=b30d3584e4e2, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jan 17 21:56:44 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358465, encodeId=3ad13584659d, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef781002, createdName=topnew, createdTime=Thu Jan 17 19:12:21 CST 2019, time=2019-01-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1935135, encodeId=4fc5193513563, content=<a href='/topic/show?id=dc5a54e869c' target=_blank style='color:#2F92EE;'>#扩心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54786, encryptionId=dc5a54e869c, topicName=扩心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 23 14:06:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829928, encodeId=c57f182992840, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jul 13 12:06:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941975, encodeId=078719419e5c4, content=<a href='/topic/show?id=338b98462fa' target=_blank style='color:#2F92EE;'>#随机研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98462, encryptionId=338b98462fa, topicName=随机研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Tue Feb 12 08:06:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460831, encodeId=0c0f14608318b, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Fri Jan 18 13:06:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358474, encodeId=b30d3584e4e2, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jan 17 21:56:44 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358465, encodeId=3ad13584659d, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef781002, createdName=topnew, createdTime=Thu Jan 17 19:12:21 CST 2019, time=2019-01-17, status=1, ipAttribution=)]
    2019-01-18 yinhl1980
  5. [GetPortalCommentsPageByObjectIdResponse(id=1935135, encodeId=4fc5193513563, content=<a href='/topic/show?id=dc5a54e869c' target=_blank style='color:#2F92EE;'>#扩心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54786, encryptionId=dc5a54e869c, topicName=扩心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 23 14:06:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829928, encodeId=c57f182992840, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jul 13 12:06:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941975, encodeId=078719419e5c4, content=<a href='/topic/show?id=338b98462fa' target=_blank style='color:#2F92EE;'>#随机研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98462, encryptionId=338b98462fa, topicName=随机研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Tue Feb 12 08:06:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460831, encodeId=0c0f14608318b, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Fri Jan 18 13:06:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358474, encodeId=b30d3584e4e2, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jan 17 21:56:44 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358465, encodeId=3ad13584659d, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef781002, createdName=topnew, createdTime=Thu Jan 17 19:12:21 CST 2019, time=2019-01-17, status=1, ipAttribution=)]
    2019-01-17 天地飞扬

    学习了,谢谢分享!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1935135, encodeId=4fc5193513563, content=<a href='/topic/show?id=dc5a54e869c' target=_blank style='color:#2F92EE;'>#扩心病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54786, encryptionId=dc5a54e869c, topicName=扩心病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Sep 23 14:06:00 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829928, encodeId=c57f182992840, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jul 13 12:06:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941975, encodeId=078719419e5c4, content=<a href='/topic/show?id=338b98462fa' target=_blank style='color:#2F92EE;'>#随机研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98462, encryptionId=338b98462fa, topicName=随机研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Tue Feb 12 08:06:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460831, encodeId=0c0f14608318b, content=<a href='/topic/show?id=b8012e675d7' target=_blank style='color:#2F92EE;'>#停药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27675, encryptionId=b8012e675d7, topicName=停药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c6d6379100, createdName=yinhl1980, createdTime=Fri Jan 18 13:06:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358474, encodeId=b30d3584e4e2, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jan 17 21:56:44 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358465, encodeId=3ad13584659d, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef781002, createdName=topnew, createdTime=Thu Jan 17 19:12:21 CST 2019, time=2019-01-17, status=1, ipAttribution=)]
    2019-01-17 topnew

    学习学习谢谢分享

    0

相关资讯

A&R: 接受甲氨蝶呤治疗的类风湿关节炎患者合用Tofacitinib(CP-690,550)的临床随机研究

来自荷兰莱顿大学医学中心的Desiree van der Heijde等人进行了一项研究,该项为期24周的三期研究的目的是检验Tofacitinib对甲氨蝶呤(MTX)疗效不佳的类风湿关节炎(RA)患者的关节结构的保护的作用。数据来源于第12周的中期分析报告。研究结果在线发布在2013年3月的ARTHRITIS & RHEUMATISM(关节炎与风湿病)上。研究者发现,接受MTX治疗的RA